Transversalis Fascia Plane vs Ilioinguinal and Iliohypogastric Nerve Block for the Treatment of CPIP
Launched by DISKAPI TEACHING AND RESEARCH HOSPITAL · Mar 11, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different methods to help relieve chronic pain in the groin area that some people experience after having hernia surgery. The two treatments being compared are called the transversalis fascia plane block (TFP) and the ilioinguinal and iliohypogastric nerve block. Both methods use ultrasound to guide the injection, and the researchers want to see which one works better for patients who have been in pain for more than 12 weeks and have not found relief from other treatments.
To participate in this trial, you need to be at least 18 years old and have been experiencing groin pain for over three months after your hernia surgery. However, if your pain is due to other medical issues, if you are pregnant, or if you have certain bleeding disorders or serious mental health conditions, you may not be eligible. If you join the study, you will be asked to rate your pain before and after receiving one of the treatments, helping the researchers understand which option is more effective. The trial is currently recruiting participants, and both men and women can take part.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Complaints of inguinal pain \>12 weeks post-herniorrhaphy surgery
- • \>18 years of age
- • Failure of conservative pain management
- Exclusion Criteria:
- • Other causes of inguinal pain (haematoma, infection, tubo-ovarian disease, abscess, etc., gynaecological, urological and organic pathologies after inguinal hernia, etc.)
- • Pregnancy
- • Coagulopathy, antiaggregant/anticoagulant/antiplatelet use
- • Unstable psychiatric illness
About Diskapi Teaching And Research Hospital
Diskapi Teaching and Research Hospital is a prominent medical institution dedicated to advancing healthcare through innovative clinical research and education. As a leading sponsor of clinical trials, the hospital is committed to enhancing patient outcomes and contributing to medical knowledge across various disciplines. With a focus on rigorous scientific protocols and ethical standards, Diskapi leverages its state-of-the-art facilities and a multidisciplinary team of experts to conduct trials that explore new therapeutic options and improve existing treatments. Through collaboration with healthcare professionals and researchers, Diskapi aims to translate research findings into practical applications that benefit patients and the broader medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ankara, , Turkey
Patients applied
Trial Officials
Gevher Rabia Genc Perdecioğlu
Study Chair
Diskapi TRH
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported